Board members, management and employees acquire Hansa Medical shares and warrants
Hansa Medical AB (publ) today announced that board members, management and employees have acquired shares and warrants in the company.
Hansa Medical’s CEO Göran Arvidson has acquired 30,000 shares and 150,000 warrants. Following the acquisition, Göran Arvidson’s total holding in Hansa Medical amounts to 33,000 shares and 150,000 warrants.
The chairman of the board, Birgit Stattin Norinder, has acquired 6,000 shares. Following the acquisition, Birgit Stattin Norinder’s total shareholding in the company amounts to 29,205 shares.
Board member Per-Olof Wallström has acquired 6,000 shares. Following the acquisition, Per-Olof Wallström’s total shareholding in the company amounts to 23,000 shares.
A total of 296,000 warrants were acquired by the company's employees, including the CEO, under the warrant program that Hansa Medical's Annual General Meeting adopted on June 2, 2015.
About Hansa Medical’s share warrant program
Each warrant entitles the holder to subscribe for one new share in Hansa Medical. Subscription for shares in accordance with the terms of the warrants may take place during the period from June 15, 2018, and June 15, 2019. The warrants are sold to the company's employees on market terms at a price established on the basis of an estimated market value of the warrants using the Black & Scholes model calculated by an independent valuation institute. The value has been set at SEK 8.40 per option based on a share price of SEK 36,04.
The information in this press release is disclosed pursuant to the Securities Markets Act or the Financial Instruments Trading Act. The information was released for public disclosure on June 10, 2015, at 08.30 CET.
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO and CFO
Mobile: 46 70-390 85 30
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB as Certified Adviser.